The Biogen Inc. (BIIB) Stock Rating Reaffirmed by Robert W. Baird

The Biogen Inc. (BIIB) Stock Rating Reaffirmed by Robert W. Baird

Biogen Inc. (NASDAQ:BIIB)‘s stock had its “positive” rating restated by stock analysts at Robert W. Baird in a research note issued on Tuesday. They currently have a $309.00 price objective on the biotechnology company’s stock. Robert W. Baird’s price target would suggest a potential upside of 8.95% from the company’s previous close.

Several other research firms have also recently commented on BIIB. Stifel Nicolaus set a $298.00 target price on Biogen and gave the stock a “hold” rating in a research note on Tuesday. Vetr cut Biogen from a “buy” rating to a “hold” rating and set a $304.83 target price for the company. in a research note on Monday, January 9th. BMO Capital Markets set a $336.00 target price on Biogen and gave the stock a “hold” rating in a research note on Sunday, January 8th. Jefferies Group reissued a “hold” rating and set a $312.00 target price on shares of Biogen in a research note on Sunday, January 8th. Finally, Cantor Fitzgerald reissued a “hold” rating on shares of Biogen in a research note on Friday, January 6th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $336.67.

Shares of Biogen (NASDAQ:BIIB) opened at 283.61 on Tuesday. The company has a market cap of $61.71 billion, a PE ratio of 16.04 and a beta of 0.74. The company has a 50-day moving average of $288.82 and a 200-day moving average of $296.22. Biogen has a 1-year low of $223.02 and a 1-year high of $333.65.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, October 26th. The biotechnology company reported $5.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.97 by $0.22. The company earned $2.96 billion during the quarter, compared to analysts’ expectations of $2.91 billion. Biogen had a return on equity of 40.02% and a net margin of 34.03%. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the firm earned $4.48 earnings per share. Equities analysts forecast that Biogen will post $20.18 EPS for the current year.

In related news, Director Robert W. Pangia sold 5,450 shares of the company’s stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $295.39, for a total value of $1,609,875.50. Following the sale, the director now owns 22,078 shares in the company, valued at approximately $6,521,620.42. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.32% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. NN Investment Partners Holdings N.V. raised its stake in Biogen by 8.4% in the fourth quarter. NN Investment Partners Holdings N.V. now owns 145,597 shares of the biotechnology company’s stock worth $41,288,000 after buying an additional 11,276 shares during the last quarter. SevenBridge Financial Group LLC raised its stake in Biogen by 2.9% in the third quarter. SevenBridge Financial Group LLC now owns 1,031 shares of the biotechnology company’s stock worth $304,000 after buying an additional 29 shares during the last quarter. First Heartland Consultants Inc. raised its stake in Biogen by 13.6% in the third quarter. First Heartland Consultants Inc. now owns 1,792 shares of the biotechnology company’s stock worth $561,000 after buying an additional 215 shares during the last quarter. Advent Capital Management DE raised its stake in Biogen by 13.3% in the third quarter. Advent Capital Management DE now owns 17,000 shares of the biotechnology company’s stock worth $5,322,000 after buying an additional 2,000 shares during the last quarter. Finally, Auxier Asset Management raised its stake in Biogen by 25.9% in the third quarter. Auxier Asset Management now owns 22,635 shares of the biotechnology company’s stock worth $7,085,000 after buying an additional 4,650 shares during the last quarter. Institutional investors and hedge funds own 86.35% of the company’s stock.

Biogen Company Profile

Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.

Related posts

Leave a Comment